Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
By Wolfgang Wick, M. Plattén, C. Meisner, J. Felsberg, G. Tabatabai, M. Simon, G. Nikkhah, K. Papsdorf, J. Steinbach, M. Sabel and 8 more. The Lancet Oncology, 2012
1,021 citations recorded by the source corpus.
Subfields: Epidemiology, Genetics, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/c89828875d9fd7a13a2191e1e78317beee752736
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
Citations in the corpus
- Glioblastoma: pathology, molecular mechanisms and markers (2015, background): “Hypermethylation of the MGMT promoter was demonstrated to serve as a predictive marker for alkylating chemotherapy in GBMs [61, 174].”
- High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, methodology): “Prognosis of mixed anaplastic oligoastrocytoma and anaplastic astrocytoma is intermediate between GBM and pure anaplastic oligodendroglioma.”